Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Excessive adverse events were encountered in a Phase I/II study of cyclophosphamide (CY) dose deescalation in a fludarabine-based conditioning regimen for bone marrow transplantation from unrelated donors in patients with severe aplastic anemia. All patients received fixed doses of antithymocyte globulin, fludarabine, and low-dose total body irradiation. The starting CY dose was 150 mg/kg, with deescalation to 100 mg/kg, 50 mg/kg, or 0 mg/kg. CY dose level 0 mg/kg was closed due to graft failure in 3 of 3 patients. CY dose level 150 mg/kg was closed due to excessive organ toxicity (n = 6) or viral pneumonia (n = 1), resulting in the death of 7 of 14 patients. CY dose levels 50 and 100 mg/kg remain open. Thus, CY at doses of 150 mg/kg in combination with total body irradiation (2 Gy), fludarabine (120 mg/m(2)), and antithymocyte globulin was associated with excessive organ toxicity.

• Publication year

  2012

• Venue

  Biology of Blood and Marrow Transplantation

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.bbmt.2012.04.014PMID 22546497PMCID PMC3677744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia

  2011cited by this paper
• Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.

  2011cited by this paper
• Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.

  2010cited by this paper
• Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party

  2010cited by this paper
• Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review

  2009influential reference
• Recent improvement in outcome of unrelated donor transplantation for aplastic anemia

  2008cited by this paper
• Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

  2007cited by this paper
• Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.

  2007cited by this paper
• Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions.

  2007cited by this paper
• Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy.

  2006cited by this paper
• Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia

  2005cited by this paper
• Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party

  2005cited by this paper
• Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

  2002cited by this paper
• Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation.

  2001cited by this paper

• Early withdrawal immunosuppression improved mixed chimerism in stem cell transplantation for pediatric aplastic anemia

  2025cites this paper
• Influence of Puncture Devices on the Accuracy of Cyclophosphamide Dosing for Chemotherapy Administration

  2025cites this paper
• A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study

  2025cites this paper
• Upfront umbilical cord blood transplantation versus immunosuppressive therapy for pediatric patients with idiopathic severe aplastic anemia.

  2024cites this paper
• Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study

  2024cites this paper
• Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia

  2023cites this paper
• Graft-Versus-Host Disease (GvHD) Prophylaxis

  2021cites this paper
• Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study

  2021cites this paper
• A modified conditioning regimen based on low‐dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity

  2021cites this paper
• Risk factors for secondary poor graft function after bone marrow transplantation in children with acquired aplastic anemia

  2020cites this paper
• Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide

  2020cites this paper
• Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin

  2019cites this paper
• Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia.

  2019cites this paper
• CD3+/CD19+ Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders.

  2019cites this paper
• Unrelated cord blood transplantation for severe aplastic anemia using intensified immunoablative conditioning regimen leading to high engraftment and survival

  2019cites this paper
• Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

  2019cites this paper
• Outcome of Fludarabine Based Conditioning in High Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single Center Study from Pakistan.

  2019cites this paper
• Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children

  2018cites this paper
• Unrelated Donor Transplants for Acquired Aplastic Anemia

  2017cites this paper
• Hematopoietic cell transplantation for aplastic anemia

  2017cites this paper
• Outcomes and healthcare utilization in children and young adults with aplastic anemia: A multiinstitutional analysis

  2017cites this paper
• Hematological Disorders in Children

  2017influential citation
• Diagnosis and Treatment of Aplastic Anemia

  2017cites this paper
• Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning

  2017cites this paper
• 减低剂量环磷酰胺的预处理方案对重型再生障碍性贫血同胞全相合外周血造血干细胞移植疗效的影响

  2017cites this paper
• Childhood Aplastic Anemia

  2017cites this paper
• Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia

  2016cites this paper
• Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.

  2016cites this paper
• The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.

  2016cites this paper
• Transplantation for bone marrow failure: current issues.

  2016cites this paper
• Alternative donor transplants for severe aplastic anemia: current experience.

  2016cites this paper
• Transplantation for bone marrow failure: current issues

  2016cites this paper
• Allogeneic stem cell transplantation for non-malignant diseases

  2016cites this paper
• Allogeneic hematopoietic stem cell transplantation in children with aplastic anemia.

  2015cites this paper
• Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

  2015cites this paper
• Sweet spot for cyclophosphamide: a balancing act.

  2015cites this paper
• Making strides and meeting challenges in pediatric allogeneic hematopoietic cell transplantation clinical trials in the United States: Past, present and future.

  2015cites this paper
• Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia

  2015cites this paper
• Alternative donor transplant of benign primary hematologic disorders

  2015cites this paper
• Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.

  2015cites this paper
• Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

  2014cites this paper
• Bone marrow transplantation for acquired severe aplastic anemia.

  2014cites this paper
• Pilot trial of risk‐adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia

  2014cites this paper
• A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia

  2014cites this paper
• Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.

  2014cites this paper
• Pleurisy as a novel clinical manifestation associated with human herpesvirus 6 after unrelated cord blood transplantation

  2014cites this paper
• HCT for nonmalignant disorders.

  2013cites this paper
• Less could be better: The case for reducing the dose of cyclophosphamide for children undergoing allogeneic stem cell transplant for severe aplastic anemia

  2013influential citation
• Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia

  2013cites this paper
• Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia

  2013cites this paper
• Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia.

  2012cites this paper